Anzeige
Meldung des Tages: Unglaubliche News: Nasdaq-Smallcap – Diese KI erkennt, was kein Labor sehen kann!

Sanofi

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
76,63 €
+0,00 €
0,00%
11:14:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
102,65 Mrd. €
Streubesitz
43,33%
KGV
10,68
Dividende
3,92 EUR
Dividendenrendite
4,76%
Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,98: JU0QQP
Werbung

Ad-hocs

05.03.26 - GlobeNewswire
Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi’s Board of Directors proposes the appointment of Christel  Heydemann as an independent director Paris, March  5 , 202 6 . The Board of Directors of Sanofi has decided to ...
04.03.26 - GlobeNewswire
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an ...
02.03.26 - GlobeNewswire
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third ...
27.02.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, ...
24.02.26 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
17.02.26 - GlobeNewswire
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026 . Sanofi announces today the ...
17.02.26 - GlobeNewswire
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE ...
16.02.26 - GlobeNewswire
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season
12.02.26 - GlobeNewswire
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi
Belén Garijo to become Chief Executive Officer of Sanofi
10.02.26 - GlobeNewswire
Press Release: Sanofi completes the acquisition of Dynavax
Sanofi completes the acquisition of Dynavax
09.02.26 - GlobeNewswire
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only ...
03.02.26 - GlobeNewswire
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
Sanofi announces the signing of a share buyback mandate for up to €1 billion
30.01.26 - GlobeNewswire
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-​vs-host disease
29.01.26 - GlobeNewswire
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
23.01.26 - GlobeNewswire
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary ...
15.01.26 - GlobeNewswire
Press Release: Myqorzo and Redemplo approved in China
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores ...
12.01.26 - GlobeNewswire
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
05.01.26 - GlobeNewswire
Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-​modifying therapy to delay the onset ...
24.12.25 - GlobeNewswire
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
24.12.25 - GlobeNewswire
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-​relapsing secondary progressive multiple sclerosis

Newssuche

Videos

newspaper
04.03.26 +13,81%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »